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Post-translational modificationDexras1 is a small GTPase and plays a central role in neuronal iron trafficking. We have shown that
stimulation of glutamate receptors activates neuronal nitric oxide synthase, leading to
S-nitrosylation of Dexras1 and a physiological increase in iron uptake. Here we report that
Dexras1 is phosphorylated by protein kinase A (PKA) on serine 253, leading to a suppression of iron
influx. These effects were directly associated with the levels of S-nitrosylated Dexras1, whereby PKA
activation reduced Dexras1 S-nitrosylation in a dose dependent manner. Moreover, we found that
adiponectin modulates Dexras1 via PKA. Hence these findings suggest the involvement of the PKA
pathway in modulating glutamate-mediated ROS in neurons, and hint to a functional crosstalk
between S-nitrosylation and phosphorylation.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Living cells are constantly exposed to numerous stimuli from
their environment and hence need to adapt to rapidly changing
surroundings. Among various modes to responds to ever-
changing environment, post-translational modification (PTM) is
one of the most dynamic and rapid processes compared to tran-
scriptional or translational responses. S-nitrosylation is one of such
modifications which occurs on the cysteine of protein by attach-
ment of a nitric oxide (NO) [1,2]. S-nitrosylation is a result of a
non-enzymatically catalyzed chemical reaction [3]. Nevertheless,
there appears to be some specificity in this reaction. More than a
hundred proteins have been identified as targets of
S-nitrosylation which is associated with modification of their func-
tions or structures [1–5]. But there are many other modificationsand hence PTM becomes more complex than ever [6,7]. It is impor-
tant to understand how each modification communicates and
modulates enzyme function.
Dexras1 (RASD1) belongs to the Ras family of small G proteins
that is selectively induced by dexamethasone [8,9]. Dexras1 has a
high homology with the Ras subfamily of proteins and has all of
the conserved domains of regular GTPases. Unlike conventional
GTPases, Dexras1 contains a 7kDa C-terminal tail. Dexras1 is also
known as an activator of G-protein signaling (AGS1) or RASD1
[10]. Glutamate via NMDA receptors triggers cellular calcium entry
with calcium–calmodulin activating nNOS [11–13], whose binding
to C-terminal associated protein of nNOS (CAPON) provides a
means for NO delivery to Dexras1, leading to S-nitrosylation of
Dexras1 on cysteine-11 [8,14]. We have shown that an activated
Dexras1 further interacts with an iron import channel, divalent
metal transporter 1 (DMT1) via a scaffolding protein called
Acyl-CoA Binding Protein 3 (ACBD3) modulating neuronal iron
trafficking. This pathway further plays a critical role in glutamate
excitotoxicity as a deletion of Dexras1 dramatically reduced NMDA
toxicity in vitro and in vivo [15,16]. Moreover, Dexras1 is shown to
regulate circadian rhythm, adenylyl cyclase and G-protein-linked
neurotransmitter [17–20].
ACBD3, a scaffolding protein between Dexras1 and DMT1, is
reported to interact with protein kinase A (PKA) regulatory subunit
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Dexras1-mediated neuronal iron trafficking. Here we report that
Dexras1 is indeed phosphorylated by PKA at Serine 253 residue.
Surprisingly, we found that PKA-mediated phosphorylation of Dex-
ras1 reduces iron influx unlike its homolog, Dexras2 (also known
as Rhes or RASD2) in which PKA-mediated phosphorylation upreg-
ulates iron influx [24]. We have further examined the crosstalk
between PKA-mediated phosphorylation and S-nitrosylation as
S-nitrosylation of Dexras1 is required to activate its GTPase activity
and increase iron influx into the cells. We found that phosphoryla-
tion of Dexras1 blocks NO-mediated modulation of iron trafficking.
Hence these findings suggest that there is a functional crosstalk
between two different PTMs and may explain a potential mecha-
nism by which PKA pathway reduces iron influx and ROS genera-
tion leading to a neuronal protection against NMDA excitotoxicity.
2. Material and methods
2.1. Cells and generation of mutant constructs
HEK 293T cells were maintained in DMEM with 10% FBS, 2 mM
L-glutamine and 100 U/ml penicillin–streptomycin at 37 C with 5%
CO2 atmosphere in a humidified incubator. Wild type Rhes was
cloned into pCMV-Myc (Clonotech, Mountain View, CA) and subse-
quently S293A and S293E mutants were created with QuickChange
(Stratagene, Ipswich, MA) method according to manufacturer’s
instruction.
2.2. Iron uptake assay
Non-transferrin-bound iron (NTBI) uptake assays were per-
formed as previously described [15,25–27]. In brief, HEK293T cells
were transfected with Dexras1-Myc or mutants using Polyfect
reagent (Qiagen, Valencia, CA). After 48 h, the cells were washed
with phosphate-buffered saline (PBS) then resuspended into iron
uptake buffer (25 mM Tris, 25 mM MES, 140 mM NaCl, 5.4 mM
KCl, 5 mM glucose, 1.8 mM CaCl2 [pH 5.5]) and transferred to glass
test tubes. Ascorbic acid was added to 1 mM FeSO4 at a 44:1 ratio.
55FeCl3 (PerkinElmer Life Science, Waltham, MA) was added to the
iron/ascorbic acidmixture,whichwas then added to the cells in iron
uptake buffer to afinal concentrationof 20 lM.Cellswere incubated
at 37 C with shaking for 15 min. The cells were washed twice with
cold PBS plus 0.5 mM EDTA and harvested. An aliquot of resus-
pended cells was taken for protein assay using the Bio-Rad Protein
Assay Reagent; the protein concentrations of individual samples
were used to quantitate 55Fe incorporation (cpm/lg protein). Sam-
ples were normalized to control. Statistical comparisons of iron
uptake were performed by student’s t-test. All NBTI uptake experi-
ments were repeated at least three times, each sample in triplicate.
2.3. GST Pull-down assay
Glutathione-S-transferase (GST) or GST-tagged ACBD3 con-
structs were cotransfected with Dexras1-Myc constructs into
HEK293T cells using PolyFect (Qiagen, Valencia, CA), with a trans-
fection efficiency of greater than 90%. Cells were lysed 48 h after
transfection in buffer A (100 mM Tris [pH 7.4], 150 mM NaCl, 1%
Triton X-100, 15% glycerol, 1 mM PMSF, 25 mg/ml antipain,
50 mg/ml leupeptin, 50 mg/ml aprotinin, 25 mg/ml chymostatin,
and 25 mg/ml pepstatin). Lysates were precleared with pansorbin
cells (Calbiochem, Billerica, MA), then 1 mg of total protein was
incubated with Glutathione-Sepharose beads overnight at 4 C.
Beads were washed with wash buffer (50 mM Tris [pH 7.4],
500 mM NaCl, 10 mM b-glycerophosphate) twice, then once with
buffer A. Beads were quenched in sample buffer (100 mM Tris[pH 6.8], 10% glycerol, 250 mM b-mercaptoethanol, 2% sodium
dodecyl sulfate, and bromophenol blue). Total protein (50 mg)
was loaded as input. Rhes-Myc binding was examined using an
anti-myc antibody (EMDMillipore, Billerica, MA) followed by incu-
bation with anti-mouse secondary conjugated to horseradish per-
oxidase (HRP) (Jackson Immunoresearch Laboratories, West
Grove, PA); blots were then stripped and probed with an anti-
GST antibody conjugated to HRP to detect ACBD3. Pierce Chemilu-
minescence (Life Technologies, Grand Island, NY) was used to
detect bands on the Western blot.
2.4. In vitro phosphorylation
Immunoprecipitation and in vitro kinase assay were performed
as previously described [24]. Cells transfected with Dexras1-Myc
or Myc were lysed in buffer A, and then centrifuged at 12000g
for 10 min at 4 C. After preclearing with 125 ll of Protein A beads
prepared as a 20% (v/v) suspension for 1 h at 4 C, supernatants
were incubated with anti-Myc antibody and the immunocom-
plexes were precipitated by addition of Protein A bead suspen-
sions. The immunoprecipitates were collected by centrifugation
and washed twice with buffer A and twice with PBS. The kinase
assay was performed by incubating cell lysates in phosphatase buf-
fer containing 20 mM MgCl2 with or without k phosphatase (k
PPase) for 3 h at 30 C. After thoroughly washing with PBS three
times, protein bound beads were incubated with kinase buffer
containing 1 mM MgATP, k PPase inhibitors, and trace mount of
[c-32P] ATP for 30 min at 30 C. When indicated, protein kinases,
such as PKA, protein kinase C (PKC), and casein kinase 2 (CK2) were
added to the reaction mixture. The kinase reaction was stopped by
adding 4 SDS loading buffer and the samples were subjected to
SDS–PAGE. Protein transferred blot was exposed to X-ray film for
autoradiography. The blot was incubated with blocking buffer of
10% skim milk then proved with anti-Myc antibody for detection
of input signal. To block PKA activities in cells, 1 lM H89 was
added to the kinase buffer.
2.5. S-nitrosylation biotin switch assay
The assay will be performed as previously described [28]. In
brief, cells will be lysed and reduced cysteines will be blocked with
4 mM methyl methanethionsulfonate (MMTS). Subsequently,
S-nitrosylated cysteines will be reduced with 1 mM ascorbate
and biotinylated with 1 mM Biotin-HPDP (Life Technologies, Grand
Island, NY). The biotinylated proteins will be pulled down with
streptavidin agarose and analyzed by Western blotting.
2.6. Data analysis
All quantitative data are presented as mean ± S.E.M., if they
were derived from at least three experiments. For comparison of
multiple groups, the data were analyzed by one-way ANOVA fol-
lowed by a Tukey post hoc test. Student’s t test was employed
for directly testing the difference between two sets of independent
samples. If the P-value less than 0.05, the difference was defined as
significant. All statistical analyses were performed using GraphPad
Prism (GraphPad Software).3. Results
3.1. PKA phosphorylates Dexras1
We previously reported that Dexras1 modulates neuronal iron
trafficking via an iron import channel DMT1 [15]. Importantly, a
scaffolding protein, ACBD3 between Dexras1 and DMT1 is required
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ACBD3 also interacts with various other proteins [21,22,29], one
of which is protein kinase A (PKA) regulatory subunit and yet
PKA does not directly phosphorylate ACBD3 (data not shown).
Hence we wondered whether Dexras1 can be phosphorylated by
especially PKA. We performed in vitro phosphorylation assay uti-
lizing recombinant Dexras1 isolated from HEK293T overexpressed
with Dexras1. Purified Dexras1 was incubated with various kinases
and was only phosphorylated by PKA. Also we observed that pre-
treatment of Dexras1 with c-phosphatase further increased phos-
phorylation of Dexras1 by PKA suggesting that Dexras1 was basally
phosphorylated by PKA (Fig. 1A). Moreover, treatment of cells
with H-89, a well-known PKA inhibitor, completely abrogated
PKA-mediated phosphorylation of Dexras1 indicating that PKA
mediates the phosphorylation of Dexras1 (Fig. 1B). Since ACBD3
binds to a regulatory subunit of PKA, we investigated whether
ACBD3 had any effect on PKA-mediated phosphorylation of
Dexras1 by performing in vitro phosphorylation assay with or
without purified recombinant ACBD3. We found ACBD3 does not
affect PKA-mediated phosphorylation of Dexras1 indicating that
ACBD3 is not involved in the phosphorylation of Dexras1 by PKA
(Fig. 1C). Previously we reported that Dexras1 regulates iron influx
[15,16] and hence we wondered whether PKA-mediated phospho-
rylation modulates Dexras1-mediated iron trafficking. HEK293T
cells were overexpressed with wild type (WT) Dexras1 and treated
with either forskolin (PKA activator, 10 lM) or H-89 (PKA inhibitor,
10 lM) for 1 h. We found that PKA activator reduced iron influx
while an inhibitor of PKA increased it suggesting that PKA regu-
lates iron influx via Dexras1 (Fig. 1D).
3.2. PKA phosphorylates only serine-253 amino acid on Dexras1
We have performed a primary sequence analysis by ScanSite
(http://scansite.mit.edu) and revealed that Dexras1 indeed con-
tains putative PKA phosphorylation sites at serine 92 and serine
253. The motif is highly conserved in Dexras1 protein from all
the species examined, suggesting these two may be potential tar-
gets for PKA-mediated phosphorylation of Dexras1 (Fig. 2A). To
directly examine which amino acid is phosphorylated by PKA, we- + - + - + - +
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Phosphorylation assays were performed three times. Iron uptake experiments were repmutated each serine (S92, and S253) into alanine that cannot be
phosphorylated by a kinase. From the in vitro phosphorylation
assay utilizing HEK293T cells overexpressed with phosphodead
mutants of either S92A or S253A we generated, we found that
PKA-mediated phosphorylation was completely eliminated from
S253A and not from S92A, demonstrating that serine-253 is the
single amino acid phosphorylated by PKA (Fig. 2B). To further
understand whether PKA-mediated phosphorylation of Dexras1
has any functional consequence, we have generated phospho-
mimetic Dexras1 mutant by changing Serine 253 to glutamic acid
(S253E) and examined its effect on iron uptake. HEK293T cells
were overexpressed with WT, phosphomimetic (S253E) or phos-
phodead (S253A) and iron uptake was measured. We found that
a phosphodead mutant, S253A significantly increased iron uptake
while a phosphomimetic mutant, S253E decreased it (Fig. 2C).
We have confirmed that expression levels of each mutant and
WT Dexras1 were comparable (Fig. 2D). We further investigated
whether any of mutants show a different affinity to ACBD3 as an
interaction between ACBD3 and Dexras1 is necessary to up-
regulate iron uptake. However, we did not find any difference on
protein–protein interaction between ACBD3 and Dexras1 mutants
(Fig. 2E) suggesting that phosphorylation of Dexras1 may affect
Dexras1 GTPase activity and modulate iron influx.
3.3. PKA regulates S-nitrosylation status of Dexras1
It has been shown that Dexras1 GTPase is activated by
NO-mediated S-nitrosylation on cysteine 11 and hence NO basi-
cally functions as guanidine exchange factor for Dexras1 [8,15].
Also, we demonstrated that this modification indeed potentiates
iron trafficking in the neurons [15]. Hence we wondered whether
phosphorylation status of Dexras1 affects NO-mediated Dexras1
function. First, HEK293T cells were overexpressed with WT,
S253A and S253E Dexras1 and treated with 100 lM GSNO for
1 h, followed by iron uptake assay. We found that cells overex-
pressed with S253A showed an increase of iron uptake which
was equivalent to the result from cells overexpressed with WT
Dexras1 plus NO treatment (Fig. 3A). Moreover, NO treatment fur-
ther augmented iron uptake in cells overexpressed with S253A. On0
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were transfected into HEK293T cells and were immunoprecipitated by anti-myc antibody. In vitro phosphorylation assay was performed and the results were visualized by
autoradiography (top). Western blot image shows the loading of Myc-tagged Dexras1 protein in the reactions (bottom). (C) HEK293T cells were transfected withWT, S253E or
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NO treatment and did not display any change in iron uptake after
NO treatment (Fig. 3A).
Since S-nitrosylation of Dexras1 is necessary to activate GTPase
activity of Dexras1 leading to an increase in iron influx, and yet
S253E phosphomimetic mutant is resistant to NO treatment, we
have interrogated whether phosphorylation status affects
S-nitrosylation of Dexras1. HEK293T cells were transfected with
WT, S253A and S253E Dexras1 and treated with 100 lM GSNO
for 1 h, which was identical condition as described above
experiment. Then biotin-switch assay was performed to examine
the levels of S-nitrosylated Dexras1. We observed that
S-nitrosylation levels of a phosphodead mutant S253A was
twice higher than that of WT while S253E mutant was not
S-nitrosylated by NO treatment even though an internal control
protein, GAPDH was all S-nitrosylated throughout the conditions
(Fig. 3B). These data suggest that Serine 253 residue needs to be
a free amino acid without phosphorylation for S-nitrosylation to
occur in Dexras1.
We have shown above that Dexras1 is basally phosphorylated
and hence we wondered whether NO-treatment would promote
dephosphorylation of Dexras1 to activate its GTPase activity. To
test this, HEK293T cells were overexpressed with WT Dexras1and first pre-labeled with 32P-orthophosphate for 30 min. Then
these cells were washed with cold PBS and were treated with
100 lM GSNO for additional 1 h, which is sufficient to
S-nitrosylate and activate Dexras1. First, we noticed that levels of
phosphorylation was slightly decreased even in the absence of
NO treatment but this was not statistically significant. More
importantly, we found that NO-treatment did not facilitate
dephosphorylation of Dexras1 suggesting that S-nitrosylation-
mediated activation of Dexras1 does not promote its dephosphory-
lation and may preferentially occur on unphosphorylated Dexras1
(Fig. 3C and D).
3.4. Phosphorylation prevents S-nitrosylation of Dexras1
To further understand a crosstalk between phosphorylation and
S-nitrosylation of Dexras1, we investigated whether PKA activation
affects status of S-nitrosylated Dexras1 and iron uptake. HEK293T
cells were transfected with either WT or S253E Dexras1 and pre-
treated with different doses of forskolin for 1 h and followed by
additional GSNO treatment (100 lM, 1 h). We found that PKA acti-
vator, forskolin facilitates de-nitrosylation of WT-Dexras1 in a
dose-dependent manner while S253E mutant was neither
S-nitrosylated or modulated by PKA treatment any more
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the cells and found that forskolin treatment reduces iron uptake as
similar to a decrease in S-nitrosylated protein (Fig. 4B) suggesting
that PKA pathway actively prevent NO-mediated iron uptake path-
way via Dexras1.
3.5. Adiponectin modulates neuronal iron influx via PKA/Dexras1
pathway
We have shown that Dexras1 plays a crucial role in oxidative
stress-mediated neuronal cell death. Hence an inhibition of Dex-
ras1 via PKA may contribute to the cell survival. Adiponectin is
synthesized and secreted by adipocytes and circulates as various
molecular forms [30,31]. Obesity decreases adiponectin levels
and blunts adiponectin sensitivity, leading to insulin resistance,
diabetes, steatosis and inflammation [31,32]. Many studies have
shown that adiponectin is present in cerebrospinal fluid, and exerts
potent actions on neurons in the hypothalamus and brainstem
[33–37]. Adiponectin also has neuroprotective effects in stroke,
seizure and other pathologies in mouse models [38–42]. Because
adiponectin activates PKA pathway in peripheral tissues [43,44],we wondered whether adiponectin could modulate Dexras1-
mediated iron trafficking in neurons via PKA. We treated primary
hippocampal neuronal cultures with various doses of adiponectin
and measured iron uptake [15,27]. We confirmed that adiponectin
treatment attenuated iron influx and yet this effect was abolished
in the cultures prepared from Dexras knockout mice, suggesting
that adiponectin may modulate iron trafficking in neurons via Dex-
ras1 (Fig. 5A). Dexras1 is a small GTPase requiring GTP binding for
its activity and it has been shown that nitric oxide-mediated post-
translational modification (S-nitrosylation) is the only way to acti-
vate Dexras1 GTPase activity [14]. Hence, we examined whether
adiponectin affects the basal levels of NO production from nNOS
and found that adiponectin treatment did not influence it (data
not shown), suggesting that Dexras1 GTPase activity is suppressed
by other mechanisms. Moreover, we found that adiponectin’s abil-
ity to inhibit iron uptake was blocked by H-89 treatment which
inhibits PKA activity (Fig. 5B). We next performed inorganic phos-
phate metabolic labeling in primary hippocampal neurons and
found that adiponectin treatment indeed increased the phosphory-
lation of Dexras1 while PKA inhibitor H-89 pretreatment blocked
this modification suggesting that adiponectin modulates iron traf-
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ponectin reduces iron influx via PKA/Dexra1 pathway in neurons.
4. Discussion
In the present study, we have identified that adiponectin, which
is produced by adipose tissue phosphorylates Dexras1 via PKA and
this modification reduces Dexras1-mediated iron uptake process,
which is dependent on its GTPase activity. Importantly, phosphory-
lation of Dexras1 inhibits its S-nitrosylation, which is essential for
Dexras1 activity and our study showed that a functional crosstalk
between two different modifications further modifies an enzyme
activity.
Dexras1 belongs to Ras superfamily and Rhes (Dexras2) is the
only RAS homology that closely resembles Dexras1 with 62%
amino acid homology. Both of them contain an extra 7kDa tail in
C-terminal region and its roles are not fully understood. Whereas
Dexars1 is stimulated by glucocorticoid, Rhes is selectively induced
by thyroid hormone. Most strikingly, Rhes is selectively expressed
in striatum and involved in pathogenesis of Huntingdon’s disease.
Moreover, it mediates mTOR signaling and L-DOPA-induced dyski-
nesia [45] while Dexras1 does not regulate mTOR pathway
(unpublished results, Chen, Y. and Kim, S.F.). Previously we have
reported that Rhes can indeed bind to ACBD3 and modulate iron
trafficking in the neuron and iron uptake is up-regulated by PKA
[24]. Interestingly, our new study examining the relationship
between PKA and Dexras1 demonstrated that indeed Dexras1 is
basally phosphorylated and yet its phosphorylation by PKA led to
a decrease of iron influx unlike Rhes. It has been shown before that
S-nitrosylation, NO-mediated PTM, acts as a guanidine exchange
factor (GEF) for Dexras1 and activates its GTPase activity, leading
to an increase of iron influx in neurons [8]. However, the phospho-
rylation status of Dexras1 seems to limit the degree of Dexras1activation via S-nitrosylation. In contrast, we have demonstrated
that Rhes is not S-nitrosylated via NO treatment even though puta-
tive S-nitrosylation target cysteine is conserved in both Dexras1
and Rhes. Moreover, NO-treatment did not affect iron uptake in
HEK293T cells overexpressed with Rhes [24]. Hence even though
both Rhes and Dexras1 participates in iron uptake and are regu-
lated by PKA, their precise mechanisms are not likely identical.
Therefore, the converse regulation of enzyme activity by phospho-
rylation and S-nitrosylation is very unique for Dexras1. However, it
is not clear how a negatively charged S253 inhibits S-nitrosylation
at C11 in Dexras1. Nevertheless, it is interesting to point out that
the phosphorylation occurs in the unique tail region. It is less likely
that phosphorylation of S253 is directly blocking the access of NO
to C11. Instead, we speculate that phosphorylation at S253 may
slightly change the structure of Dexras1 and possibly bury C11 site.
In fact, C11 site is also conserved in Dexras2 (also known as Rhes)
with high homology and yet we found Dexras2 is not S-
nitrosylated by NO treatment.
Our previous studies demonstrated that Dexras1 plays a central
role in either glutamate/NMDA or NO-mediated cell death path-
way as a genetic deletion of Dexras1 drastically reduced cell death
induced by either NMDA excitotoxicity or excess NO treatment
suggesting that Dexras1 may be a viable target to treat glutamate
toxicity [15,16]. Our current study demonstrated that Dexras1
activity, or Dexras1-mediated iron influx can be reduced by a
PKA dependent manner. In fact many studies demonstrated that
PKA pathway is involved in neuroprotection mechanism via vari-
ous pathways. The transcription factor myocyte-enhancer factor
2 (MEF2) is a known to be required for neuronal survival and it
has been shown that PKA-mediated phosphorylation of MEF2 is a
key step in modulating its DNA binding activity and ability to pro-
mote neuronal survival [46]. Moreover, Dore’s group identified that
neuroprotective effect of prostaglandin system also requires an
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Fig. 5. Adiponectin regulates iron trafficking in neurons via PKA/Dexras1 depen-
dent manner. (A) Primary hippocampal neurons were treated with adiponectin for
8 h and iron uptake assay was performed w/out H-89, PKA inhibitor. Data represent
triplicate samples. (B) Primary hippocampal cultures were prepared from either WT
or Dexras1 knockout mice and iron uptake assay was performed after treating cells
with adiponectin for 4 h. (C) Primary hippocampal neurons are treated with
adiponectin 10 lM for 8 h and metabolic labeling was performed. Dexras1 protein
was immunoprecipitated and detected by autoradiography. Input levels were
detected by immunoblotting. Phosphorylation assays were performed three times.
Iron uptake experiment was repeated five times, each sample in at least triplicate.
3218 Y. Chen et al. / FEBS Letters 589 (2015) 3212–3219activation of PKA pathway [47]. It appears that PKA-mediated sur-
vival pathway is not limited to neurons. Cell death in rat rod pho-
toreceptor can be blocked by interleukin-4 in a PKA dependent
manner [48]. Hence it is tempting to speculate that a stimulus or
reagent which can induce PKA pathway may serve as a neuropro-
tective reagents by reducing iron-catalyzed oxidative stress via a
suppression of Dexras1. In fact, it has been shown that PKA activa-
tion can reduce iron uptake pathway [49]. However it is important
to mention that PKA pathway is not always associated with a cell
survival pathway [50,51]. An excess lipid can lead to a neuronal
cell death and an initiation of apoptotic pathway was triggered
by PKA-dependent manner [52]. Hence it appears important to
examine what triggered a cell death pathway and this may deter-
mine whether PKA pathway is involved with cytoprotective or
cytotoxic pathways. Our study identified that activation of PKA
can reduce iron uptake and consequently ROS generation induced
by NMDA/NO pathway.
In this study, we have identified that adiponectin, a cytokine
produced by adipose tissue, indeed down-regulates Dexras1 iron
flux pathway via PKA. Adiponectin is one of the most abundanthormone in the plasma and its level is inversely related to body
fat content. It is known to regulate various metabolic processes
such as glucose homeostasis or fatty acid oxidation. However,
recent studies showed that adiponectin may have some non-
metabolic functions in particular in the brain. Adiponectin has neu-
roprotective effects in stroke, seizure and other pathologies in
mouse models, which are strongly associated with oxidative
stress-mediated damages [38–42]. Therefore, our findings further
strengthen a notion that PKA/Dexras1 pathway may serve as a tar-
get to protect neurons against neurotoxicity. Also, other studies
have reported that adiponectin promotes neurogenesis, decreases
depression, and mediates the effects of exercise on hippocampal
neurons [37]. It has been shown that nNOS/CAPON-ERK pathway
is upregulated in anxiogenic condition and Dexras1 is mediating
this pathway [53]. Our studies showing adiponectin as a negative
regulator of Dexras1 pathway may provide a molecular link
between energy balance and anxiety.
NO is a gaseous molecule which is produced by a group of
enzymes called nitric oxide synthase and can diffuse through a
membrane to some degree. Hence it can function as a signaling
molecule that acts in many tissues to regulate a diverse range of
physiological processes, which include vasodilation, neuronal
function, inflammation and immune function [11,13,54]. One of
the key cellular roles of NO is reversible protein modification, such
as S-nitrosylation, a covalent addition of an NO group to a cysteine
thiol/sulfhydryl (RSH or, more properly, thiolate anion, RS-), result-
ing in formation of an S-nitrosothiol derivative (RSNO) [1,55]. In
analogy to phosphorylation by kinases, S-nitrosylation by NOSs
influences protein activity, protein–protein interactions, and pro-
tein location, thus serving as the prototypical redox-based signal
[55]. S-Nitrosylation is readily reversible with high spatial and
temporal specificity. In the current study, we have revealed that
two analogous PTMs influence each other and provide an extra
layer of complexity on how neuronal iron status or iron-
catalyzed redox status is modulated.
In conclusion, we have identified that Dexras1-mediated iron
trafficking is not only regulated by NO but also PKA pathway which
is associated with various neurotransmitters or cytokines [44,56].
In particular we have shown that Dexras1 is negatively modulated
by adiponectin, which plays crucial roles on energy balance, neuro-
protection, and neurogenesis. Hence our studies may provide
potential mechanism by which PKA pathway may protect neurons
from NMDA excitotoxicity. Moreover, there are numerous studies
describing that iron status in the brain influence neuro-
development while there is very few studies describing the role
of neuronal iron or its trafficking on any specific behavior. Our
studies will provide a promising groundwork which can be further
extended to investigate how Dexras1/iron pathway modulate neu-
ral function and consequently afford a novel therapeutic strategies
to treat patients with neuropsychiatric diseases.
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